{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:18:41Z","timestamp":1782778721450,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA036670"],"award-info":[{"award-number":["R01 DA036670"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA047867"],"award-info":[{"award-number":["R01 DA047867"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA042790"],"award-info":[{"award-number":["R01 DA042790"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM103644"],"award-info":[{"award-number":["P20 GM103644"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["UD9RH33633"],"award-info":[{"award-number":["UD9RH33633"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ypmed.2021.106765","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T10:51:07Z","timestamp":1629111067000},"page":"106765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"P2","title":["Opioid use disorder treatment in rural settings: The primary care perspective"],"prefix":"10.1016","volume":"152","author":[{"given":"Valerie S.","family":"Harder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Villanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lindsey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diann E.","family":"Gaalema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel H.","family":"Schafrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey C.","family":"Sigmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2021.106765_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","article-title":"A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices","volume":"54","author":"Andraka-Christou","year":"2018","journal-title":"Int. J. Drug. Policy"},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder","volume":"15","author":"Andrilla","year":"2017","journal-title":"Ann. Fam. Med."},{"issue":"1","key":"10.1016\/j.ypmed.2021.106765_bb0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"J. Rural. Health"},{"key":"10.1016\/j.ypmed.2021.106765_bb0020","series-title":"The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome","author":"Ball","year":"1991"},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/ADM.0000000000000400","article-title":"Gaps in the substance use disorder treatment referral process: provider perceptions","volume":"12","author":"Blevins","year":"2018","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.ypmed.2021.106765_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.ypmed.2021.106765_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ypmed.2021.106765_bb0045","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/1475-6773.00151","article-title":"Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations","volume":"38","author":"Friedmann","year":"2003","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.ypmed.2021.106765_bb0050","series-title":"Issue brief. Expanding Low Barrier Access to Medication Assisted Treatment: Issue Brief","article-title":"Challenges and strategies to expanding MAT within primary care: provider perspectives","author":"Gallo","year":"2019"},{"key":"10.1016\/j.ypmed.2021.106765_bb0055","series-title":"Drug Alcohol Depend","first-page":"107527","article-title":"U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018","volume":"204","author":"Ghertner","year":"2019"},{"issue":"6","key":"10.1016\/j.ypmed.2021.106765_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1\u20132","key":"10.1016\/j.ypmed.2021.106765_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10826084.2012.736050","article-title":"Triage in opioid replacement therapy: what\u2019s the wait?","volume":"48","author":"Harlow","year":"2013","journal-title":"Subst. Use Misuse"},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/00952990802122358","article-title":"Comparison of characteristics of opioid-using pregnant women in rural and urban settings","volume":"34","author":"Heil","year":"2008","journal-title":"Am. J. Drug. Alcohol. Abuse"},{"issue":"1","key":"10.1016\/j.ypmed.2021.106765_bb0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jrh.12178","article-title":"Assessing differences in the availability of opioid addiction therapy options: rural versus urban and American Indian reservation versus nonreservation","volume":"33","author":"Hirchak","year":"2017","journal-title":"J. Rural. Health"},{"issue":"18","key":"10.1016\/j.ypmed.2021.106765_bb0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ypmed.2021.106765_bb0085","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/add.14436","article-title":"Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder","volume":"114","author":"Jones","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.ypmed.2021.106765_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"issue":"12","key":"10.1016\/j.ypmed.2021.106765_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm6912a1","article-title":"Patterns and characteristics of methamphetamine use among adults - United States, 2015-2018","volume":"69","author":"Jones","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2021.106765_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.10.005","article-title":"Buprenorphine prescribing practice trends and attitudes among New York providers","volume":"74","author":"Kermack","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","article-title":"Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence","volume":"25","author":"Kissin","year":"2006","journal-title":"J. Addict. Dis."},{"issue":"1","key":"10.1016\/j.ypmed.2021.106765_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review","volume":"20","author":"Louie","year":"2019","journal-title":"BMC Fam. Pract."},{"issue":"Suppl. 1","key":"10.1016\/j.ypmed.2021.106765_bb0115","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/QAI.0b013e31820a9a82","article-title":"Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings","volume":"56","author":"Lum","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.ypmed.2021.106765_bb0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7326\/M19-3975","article-title":"Medication for opioid use disorder: a national survey of primary care physicians","volume":"173","author":"McGinty","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ypmed.2021.106765_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jsat.2019.07.013","article-title":"Implementation of the hub and spoke model for opioid use disorders in California: rationale, design and anticipated impact","volume":"108","author":"Miele","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ypmed.2021.106765_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13011-015-0009-2","article-title":"Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio","volume":"10","author":"Molfenter","year":"2015","journal-title":"Subst. Abuse. Treat. Prev. Policy."},{"issue":"3","key":"10.1016\/j.ypmed.2021.106765_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.ypmed.2021.106765_bb0140","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/pds.4984","article-title":"Rise and regional disparities in buprenorphine utilization in the United States","volume":"29","author":"Pashmineh Azar","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"10.1016\/j.ypmed.2021.106765_bb0145","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/pds.1626","article-title":"Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type","volume":"17","author":"Paulozzi","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ypmed.2021.106765_bb0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2147\/JPR.S136478","article-title":"Provider confidence in opioid prescribing and chronic pain management: results of the opioid therapy provider survey","volume":"10","author":"Pearson","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ypmed.2021.106765_bb0155","unstructured":"Petterson, S., Wilkinson, E., Kessler, A.C., Stone, C., Basemore, A., 2018. The State of Primary Care Physician Workforce: Vermont, Center, T.R.G., Washington, D.C."},{"issue":"7","key":"10.1016\/j.ypmed.2021.106765_bb0160","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/10826084.2014.891615","article-title":"Barriers to substance abuse treatment in rural and urban communities: counselor perspectives","volume":"49","author":"Pullen","year":"2014","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.ypmed.2021.106765_bb0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13722-019-0175-z","article-title":"Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice","volume":"14","author":"Pytell","year":"2019","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.ypmed.2021.106765_bb0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ypmed.2021.106765_bb0175","doi-asserted-by":"crossref","first-page":"105785","DOI":"10.1016\/j.ypmed.2019.105785","article-title":"Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system","volume":"128","author":"Rawson","year":"2019","journal-title":"Prev. Med."},{"key":"10.1016\/j.ypmed.2021.106765_bb0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","article-title":"The Washington state hub and spoke model to increase access to medication treatment for opioid use disorders","volume":"108","author":"Reif","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ypmed.2021.106765_bb0185","doi-asserted-by":"crossref","first-page":"948789","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to opioid treatment programs in the United States","volume":"2011","author":"Rosenblum","year":"2011","journal-title":"J. Environ. Public Health"},{"issue":"5","key":"10.1016\/j.ypmed.2021.106765_bb0190","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am. J. Public Health"},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: challenges and future directions","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ypmed.2021.106765_bb0200","series-title":"Expanding Access to Medication-Assisted Treatment (MAT) through Primary Care Practices: Findings from the Maine Health Access Foundation's Addiction Care Program (Years One and Two)","author":"Smith","year":"2019"},{"key":"10.1016\/j.ypmed.2021.106765_bb0205","series-title":"Addressing Unhealthy Alcohol Use in Maine: A Programmatic Evaluation of the Time to Ask Pilot Project: A Blended Learning Education Program Addressing Unhealthy Alcohol Use for Interprofessional Teams in Primary Care","author":"Smith","year":"2019"},{"key":"10.1016\/j.ypmed.2021.106765_bb0210","author":"Smith"},{"key":"10.1016\/j.ypmed.2021.106765_bb0215","author":"Smith"},{"issue":"3","key":"10.1016\/j.ypmed.2021.106765_bb0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"issue":"11","key":"10.1016\/j.ypmed.2021.106765_bb0225","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ypmed.2021.106765_bb0230","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.ypmed.2021.106765_bb0235","author":"U.S. Census Bureau"},{"key":"10.1016\/j.ypmed.2021.106765_bb0240","author":"U.S. Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ypmed.2021.106765_bb0245","author":"U.S. Department of Health & Human Services"},{"key":"10.1016\/j.ypmed.2021.106765_bb0250","series-title":"Access to Treatment for Opioid Use Disorder: A Survey of Addiction Medicine Physicans on Telemedicine and Medication-Assisted Treatment","author":"University of Michigan Behavioral Health Workforce Research Center","year":"2019"},{"key":"10.1016\/j.ypmed.2021.106765_bb0255","author":"Vermont Department of Health"},{"key":"10.1016\/j.ypmed.2021.106765_bb0260","author":"Vermont Department of Health"},{"issue":"22","key":"10.1016\/j.ypmed.2021.106765_bb0265","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies--tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/08897077.2013.797540","article-title":"Internal medicine residents\u2019 training in substance use disorders: a survey of the quality of instruction and residents\u2019 self-perceived preparedness to diagnose and treat addiction","volume":"34","author":"Wakeman","year":"2013","journal-title":"Subst. Abus."},{"issue":"4","key":"10.1016\/j.ypmed.2021.106765_bb0275","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/08897077.2016.1187240","article-title":"Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists","volume":"37","author":"Wakeman","year":"2016","journal-title":"Subst. Abus."},{"issue":"9","key":"10.1016\/j.ypmed.2021.106765_bb0280","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.ypmed.2021.106765_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1360-0443.2006.01686.x","article-title":"Staff attitudes towards working with drug users: development of the drug problems perceptions questionnaire","volume":"102","author":"Watson","year":"2007","journal-title":"Addiction"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521003340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521003340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:07:11Z","timestamp":1777475231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743521003340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":57,"alternative-id":["S0091743521003340"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106765","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid use disorder treatment in rural settings: The primary care perspective","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106765"}}